Therapeutic cancer vaccines based on molecularly defined human tumor antigens.
The results of numerous phases I and II clinical trials testing the safety and immunogenicity of various cancer vaccine formulations based on cytolytic T lymphocytes (CTLs)-defined tumor antigens have been reported recently. Specific T cell responses can be detected in only a fraction of immunized patients. A smaller but significant fraction of these patients have objective tumor responses. Efficient therapeutic vaccination should aim at boosting naturally occurring anti-tumor responses and at sustaining a large contingent of tumor antigen-specific and fully functional effector T cells at tumor sites.
Romero
Pedro
P
Divison of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Avenue Pierre-Decker 4, 1005 Lausanne, Switzerland. pedro.romero@isrec.unil.ch
Pittet
Mikael
M
Dutoit
Valerie
V
Zippelius
Alfred
A
Liénard
Danielle
D
Lejeune
Ferdy
F
Guillaume
Philippe
P
Rimoldi
Donata
D
Valmori
Danila
D
Speiser
Daniel E
DE
Cerottini
Jean-Charles
JC
D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines